RACE ONCOLOGY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.295 AUD | +0.39% |
|
-5.47% | +54.17% |
| Mar. 26 | Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6% | MT |
| Mar. 18 | Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index | CI |
| Sales 2022 | 708K 462K | Sales 2023 | 3.13M 2.04M | Capitalization | 200M 130M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -7.18M | Net income 2023 | -9M -5.87M | EV / Sales 2022 | 392 x |
| Net cash position 2022 | 33.54M 21.88M | Net cash position 2023 | 21.52M 14.04M | EV / Sales 2023 | 56.9 x |
| P/E ratio 2022 |
-26.7
x | P/E ratio 2023 |
-19.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.84% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.39% | ||
| 1 week | -5.47% | ||
| Current month | -8.80% | ||
| 1 month | -5.47% | ||
| 3 months | +93.28% | ||
| 6 months | +28.86% | ||
| Current year | +54.17% |
1 week
1.28
1.40
1 month
1.281.74
Current year
0.641.81
1 year
0.641.93
3 years
0.644.04
5 years
0.054.23
10 years
0.054.23
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Tillett
CEO | Chief Executive Officer | - | Nov. 21 |
| Chief Tech/Sci/R&D Officer | - | 23-06-30 | |
Tim Hammond
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Smith
BRD | Director/Board Member | 61 | 23-06-28 |
Borje Andersson
PRN | Corporate Officer/Principal | - | 20-01-31 |
Phillip Lynch
BRD | Director/Board Member | - | 20-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.295 | +0.39% | 5 133 |
| 24-04-24 | 1.29 | -1.15% | 26,149 |
| 24-04-23 | 1.305 | +2.35% | 44,115 |
| 24-04-22 | 1.275 | -6.93% | 202,589 |
| 24-04-19 | 1.37 | -1.44% | 98,696 |
Delayed Quote Australian S.E., April 25, 2024 at 08:45 pm EDT
More quotes
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
Calendar
2024-08-22
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +54.17% | 139M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- RAC Stock
